Investor Relations
Abcam IR Home
Share price & chart
Reports & accounts / Financial Calendar
Regulatory news (RNS)
Contacts & advisors
Governance
CSR statement
Directors
Major shareholders
Other Documents
The Abcam story
About research antibodies
Abcam company news
Main Abcam website

REG-ABCAM Plc Additional Listing

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20091116:RnsP4968C
                                                                                                                       .
RNS Number : 4968C  
  
ABCAM Plc  
  
16 November 2009  
  
16 November 2009  
  
ABCAM PLC ("Abcam" or "the Company")   
  
Additional Listing   
  
Application has been made to AIM for the admission of 268,359 ordinary shares of 
1p each in the Company to trading. These shares, which will rank pari passu in 
all respects with the existing shares in issue, have been allotted pursuant to 
the exercise of options by employees of the Company. Admission is expected to 
become effective on 17 November 2009.   
  
In addition, application has been made to AIM for the block listing of 1,668,456 
ordinary shares of 1p each in the Company. These shares will be issued as 
appropriate, over time, in connection with the following option schemes:   
  
 
  28,456 under the Abcam SAYE Scheme                      
  1,000,000 under the Abcam 2005 Share Option Scheme      
  100,000 under the Abcam plc Share Incentive Plan        
  40,000 under the Abcam Unapproved Share Option Scheme   
  100,000 under the Abcam 2009 Company Share Option Plan  
  400,000 under the Abcam plc Long Term Incentive Plan    
  
  
When issued the shares will rank pari passu in all respects with the existing 
shares in issue. It is expected that the block listing will become effective on 
17 November 2009.   
  
For further information please contact:   
  
 
  Abcam                                               + 44 (0) 1223 696000   
  Jeffrey Iliffe, Chief Financial Officer                                    
                                                                             
  Numis Securities                                    + 44 (0) 207 260 1000  
  Michael Meade / Nick Westlake - Nominated Adviser                          
  James Black - Corporate Broking                                            
                                                                             
  Buchanan Communications                             + 44 (0) 20 7466 5000  
  Mark Court/ Stasa Filiplic                                                 
  
  
Notes for editors:   
  
About Abcam plc   
  
Abcam is a producer and distributor of research-grade antibodies headquartered 
in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA, 
Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and 
trades under the ticker symbol ABC. The Company produces and distributes its own 
and third-party produced antibodies to academic and commercial users throughout 
the world. Product ordering is available through the Company's website 
www.abcam.com, where customers are also able to access up-to-date and detailed 
technical product data sheets. All the antibodies are sold under the Abcam brand 
name and the Company's vision is to build the world's largest online resource of 
high-quality and commercially viable antibodies. Abcam now has an online 
catalogue of over 56,000 products, most of which are antibodies, from over 250 
suppliers and employs 243 staff in its four operating companies.  
  
 
This information is provided by RNS  
  
The company news service from the London Stock Exchange  
  
  END  
  
LISFGMMMFFGGLZM  
  

---

back to RNS news